Janux Therapeutics (JANX) Other financing activities (2020 - 2026)

Janux Therapeutics (JANX) has 6 years of Other financing activities data on file, last reported at $3.5 million in Q1 2026.

• On a quarterly basis, Other financing activities rose 293.45% year-over-year to $3.5 million in Q1 2026; TTM through Mar 2026 was $7.7 million, a 85.67% increase from a year earlier, with the FY2021 full-year figure at $204.2 million, changed N/A from the prior year.
• Other financing activities for Q1 2026 stood at $3.5 million, up from $901000.0 in the prior quarter.
• Over the last five years, Other financing activities for JANX reached as high as $3.5 million in Q1 2026 and fell as low as $901000.0 in Q1 2025.
• Historically, Other financing activities has averaged $1.9 million across 4 years, with a median of $1.6 million in 2023.
• Across the five-year window, Other financing activities plunged 45.62% in 2025 and surged 293.45% in 2026, its largest moves.
• Year by year, Other financing activities stood at $1.6 million in 2023, then advanced by 4.87% to $1.7 million in 2024, then plunged by 45.62% to $901000.0 in 2025, then jumped by 293.45% to $3.5 million in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were $3.5 million in Q1 2026, $901000.0 in Q1 2025, and $1.7 million in Q1 2024.